Patents by Inventor Eric C. Carnes

Eric C. Carnes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190262469
    Abstract: The present disclosure relates to protocells that are useful in the treatment and prevention of viral infections, including but not limited to infections caused by a Hendra virus and Nipah virus (NiV). The present disclosure relates to protocells that are useful in the treatment of bacterial infections, including antibiotic-resistant bacterial infections. The protocells are coated with a lipid bi- or multilayer comprising at least one moiety that targets a viral cellular receptor and at least one moiety that ruptures a virally-infected cell membrane. The present disclosure further relates to novel mesoporous metal oxide nanoparticles and related protocells that are useful in the treatment and/or prevention of a wide variety of disorders, including a cancer or a bacterial or viral infection. Such nanoparticles and protocells can be functionalized to allow for synergistic loading of a wide variety of active ingredients.
    Type: Application
    Filed: September 2, 2016
    Publication date: August 29, 2019
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Oscar Negrete, Dan C Wilkinson, Brian S Wilkinson, David Patrick Padilla
  • Publication number: 20190091150
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: July 2, 2018
    Publication date: March 28, 2019
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Patent number: 10022327
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: July 17, 2018
    Assignees: STC.UNM, Sandia Corporation
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Publication number: 20180110831
    Abstract: The present invention is directed to protocells, which have a core and a lipid bilayer surrounding the core, with at least one CD47 molecule or an active fragment thereof in or conjugated to the lipid bilayer. The CD47 present on the lipid bilayer allows the protocell to evade phagocytosis by macrophages, and can be conjugated to the lipid bilayer via a crosslinker. The protocell can be loaded with a diagnostic or therapeutic cargo, such as a polypeptide, a nucleic acid, or a drug. The protocell can also include a targeting species for targeted delivery of the cargo to a cell. The protocell can also include an endosomolytic peptide, which promotes endosomal escape after uptake by the targeted cell. The protocells with CD47 on the lipid bilayer provide better circulation after in vivo administration compared to protocells without CD47, and are therefore particularly useful as a cargo delivery vehicle.
    Type: Application
    Filed: March 9, 2016
    Publication date: April 26, 2018
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Jacob Ongundi Agola, Kimberly Butler, Christophe Theron
  • Publication number: 20180105430
    Abstract: The present invention relates to the discovery that mesoporous silica nanoparticles may be modified in pore size from the natural mesophase by generating mesoporous materials in binary, ternary or multiphase surfactant systems to produce biphasic, triphasic or multiphase mesoporous structures. Thus, the present invention relates to methods of producing biphase, triphasic and multiphase mesoporous structures with finely tuned mesopore size and protocells which are produced therefrom and mesoporous silica nanoparticles obtained therefrom. The resulting mesoporous nanostructures may be used to create protocells having unique cargo loading and release characteristics. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
    Type: Application
    Filed: March 11, 2016
    Publication date: April 19, 2018
    Inventors: Eric C. Carnes, C. jeffrey Brinker, Darren Dunphy, Trevin Heisey
  • Publication number: 20180049984
    Abstract: The present disclosure relates to the delivery of polynucleotides and/or oligonucleotides using silica delivery platforms, e.g., silica carriers or protocells. In particular, in the present disclosure, polynucleotides in the form of plasmids expressing siRNA may be administered as cargo in the silica delivery platform to a patient or subject to inhibit and/or treat cancer in a patient. In one aspect, the silica delivery platform that have been charged with cargo comprising plasmid DNA (in particular, CRISPR ds plasmid DNA) which expresses siRNA, shRNA, mRNA and other RNA which may be used to administer these plasmids to patients in order to effect inhibition of cancer cells (especially including apoptosis of those cancer cells) and effective and/or prophylaxis of cancer, as well as numerous pathogens, including viruses, bacteria, fungi, and/or other disease states and/or conditions. In another aspect, the silica delivery platform comprises a biological package (e.g.
    Type: Application
    Filed: March 30, 2017
    Publication date: February 22, 2018
    Inventors: Charles Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Joshua Santarpia, Adrienne Celeste Greene, Oscar Negrete, Steven Branda, Ayse Muniz, Jacob Ongundi Agola, Kimberly Butler
  • Publication number: 20180028686
    Abstract: The present disclosure relates to the delivery of polynucleotides and/or oligonucleotides using silica delivery platforms, e.g., silica carriers or protocells. In particular, in the present disclosure, polynucleotides in the form of plasmids expressing siRNA may be administered as cargo in the silica delivery platform to a patient or subject to inhibit and/or treat cancer in a patient. In one aspect, the silica delivery platform that have been charged with cargo comprising plasmid DNA (in particular, CRISPR ds plasmid DNA) which expresses siRNA, shRNA, mRNA and other RNA which may be used to administer these plasmids to patients in order to effect inhibition of cancer cells (especially including apoptosis of those cancer cells) and effective and/or prophylaxis of cancer, as well as numerous pathogens, including viruses, bacteria, fungi, and/or other disease states and/or conditions. In another aspect, the silica delivery platform comprises a biological package (e.g.
    Type: Application
    Filed: March 30, 2017
    Publication date: February 1, 2018
    Inventors: Charles Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Joshua Santarpia, Adrienne Celeste Greene, Oscar Negrete, Steven Branda, Ayse Muniz, Jacob Ongundi Agola, Kimberly Butler
  • Publication number: 20170232115
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: December 15, 2016
    Publication date: August 17, 2017
    Inventors: Carlee Erin Ashley, C. Jeffrey Brinker, Eric C. Carnes, Mohammed Houman Fekrazad, Linda A. Felton, Oscar Negrete, David Patrick Padilla, Brian S. Wilkinson, Dan C. Wilkinson, Cheryl L. Willman
  • Publication number: 20170165375
    Abstract: The invention provides novel antibiotic protocells comprising mesoporous nanoparticles encapsulated within a lipid bi- or multilayer. The nanoparticles have pore sizes and surface chemistries that enable facile adsorption and intracellular presentation of antibiotics which are effective in the treatment of a wide variety of bacterial infections, including F. tularensis, B. pseudomallei and P. aeruginosa-related infections. Related pharmaceutical compositions and methods of treatment are also provided.
    Type: Application
    Filed: April 2, 2014
    Publication date: June 15, 2017
    Inventors: Carlee Erin Ashley, Eric C. Carnes, Terry Wu, Linda A. Felton, Darryl Y. Sasaki
  • Patent number: 9579283
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: February 28, 2017
    Assignees: STC.UNM, Sandia Corporation
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Publication number: 20160151482
    Abstract: The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.
    Type: Application
    Filed: April 2, 2014
    Publication date: June 2, 2016
    Inventors: Eric C. Carnes, C. Jeffrey Brinker, Carlee Erin Ashley
  • Publication number: 20160106671
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: December 16, 2015
    Publication date: April 21, 2016
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carlee Erin Ashley, Cheryl L. Willman
  • Publication number: 20150272885
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 1, 2015
    Inventors: Carlee Erin Ashley, C. Jeffrey Brinker, Eric C. Carnes, Mohammad Houman Fekrazad, Linda A. Felton, Oscar Negrete, David Patrick Padilla, Brian S. Wilkinson, Dan C. Wilkinson, Cheryl L. Willman
  • Publication number: 20150010475
    Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.
    Type: Application
    Filed: December 31, 2012
    Publication date: January 8, 2015
    Applicants: SANDA CORPORATION
    Inventors: C. Jeffrey Brinker, David S. Peabody, Walker Kip Wharton, Bryce Chackerian, Carlee Erin Ashley, Cheryl L. Willman, Eric C. Carnes, Katherine Epler, Robert Eric Castillo
  • Publication number: 20140301951
    Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Inventors: Juewen Liu, C. Jeffrey Brinker, Carlee Ashley, Eric C. Carnes
  • Patent number: 8734816
    Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: May 27, 2014
    Assignees: STC.UNM, Sandia Corporation
    Inventors: Juewen Liu, Jeffrey C. Brinker, Carlee Ashley, Eric C. Carnes
  • Publication number: 20140079774
    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 20, 2014
    Applicant: STC.UNM
    Inventors: C. Jeffrey Brinker, Eric C. Carnes, Carleen Erin Ashley